Test drug RMC-6236 for certain RAS mutations in advanced cancers
Treatments studied
Part of Cancer, Digestive system, Hormones & metabolism, Lungs & breathing, Skin clinical trials.
This trial tests whether RMC-6236 can treat advanced solid tumors that have specific RAS-related gene changes (especially certain KRAS G12 mutations). You may be able to join if your tumor’s DNA test shows the right mutation and your overall health is good enough for study visits.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have an advanced solid tumor that has the specific KRAS G12 or other RAS mutation the study needs
- Your tumor DNA must be identified by a DNA test (sequencing) done on tumor tissue (or as required by the study)
- You are either newly diagnosed for this cancer (treatment-naive) or have already had the standard treatment for your cancer type
- You are well enough to participate (ECOG performance status 0–1, meaning you can do most normal activity)
- Your blood and organ tests show adequate kidney, liver, and bone marrow function (per study lab requirements)
- You should not have certain brain cancer situations, and you must be able to swallow and absorb an oral medicine
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests two oral medicines (elironrasib and daraxonrasib) given alone or together to see if they can shrink tumors or slow down cancer growth in people with advanced solid tumors that have a KRAS G12C mutation. It is for people who have already tried other treatments.
This trial tests new drugs that target specific RAS mutations in advanced non-small cell lung cancer. It's for people whose cancer has a KRAS G12C, G12D, or other RAS mutation and who have already tried standard treatments.
This trial tests an experimental pill (RMC-9805) for people with solid tumors that have a specific KRAS G12D mutation. It's for those who have already tried other treatments and need new options.
This trial tests a new drug called RMC-5127 for people with advanced solid tumors that have a specific KRAS G12V mutation. The study aims to see if this targeted therapy can help when other treatments have stopped working or caused side effects.
This early-stage trial tests a new drug called INV-8989 designed to target a specific genetic mutation (KRAS G12D) found in some advanced solid cancers. The study will evaluate whether the drug is safe and if it can help shrink tumors in patients who haven't responded to standard treatments.
This early-stage trial tests a new drug called LT-010391 designed to target a specific genetic mutation (KRAS G12D) found in some solid tumors. It's for patients whose cancer has progressed despite standard treatments or who cannot tolerate them.
Hear when a new Colorectal Cancer (CRC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.